This article is a correction to:
Role of NLRP3 Inflammasome in Rheumatoid Arthritis
Hui Yin
Na Liu
Keshav Raj Sigdel
Lihua Duan- 1Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People’s Hospital, Medical College of Nanchang University, Nanchang, China
- 2Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China
- 3Department of Internal Medicine, Patan Academy of Health Sciences, Kathmandu, Nepal
A Corrigendum on
Role of NLRP3 inflammasome in rheumatoid arthritis
by Yin H, Liu N, Sigdel KR, Duan L. (2022). Front Immunol. 3:931690. doi: 10.3389/fimmu.2022.931690
In the published article, there was an error in Table 1 as published. The role of IL-18 in CAPS was displayed as “The inflammatory effects of IL-1 and IL-18 were significantly enhanced in aged mice compared with young mice”. The correct statement is “The inflammatory effects of IL-18 were significantly enhanced in young mice compared with aged mice”. The corrected Table 1 and its caption “Role of NLRP3 inflammasome in different stages of different diseases” appear below.
TABLE 1
Table 1 Role of NLRP3 inflammasome in different stages of different diseases.
In the published article, the reference in the sentence “And IL-1β induces differentiation of naive CD4 + T cells into Th17 and also promotes Th9 differentiation in concert with other cytokines. (67)” was incorrectly written as “(!!! INVALID CITATION!!! [58; 59])”. It should be “G. Xue, G. Jin, J. Fang, and Y. Lu, IL-4 together with IL-1β induces antitumor Th9 cell differentiation in the absence of TGF-β signaling. Nat Commun 10 (2019) 1376.” and “E.V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8 (2007) 942-9”.
The reference in the sentence “Recent studies have noted that the imbalance of Treg/Th17 cells affects the inflammatory response in RA.(93)” was incorrectly written as “(!!! INVALID CITATION!!! [77])”. It should be “S. Jin, S. Sun, H. Ling, J. Ma, X. Zhang, Z. Xie, N. Zhan, W. Zheng, M. Li, Y. Qin, H. Zhao, Y. Chen, X. Yang, and J. Wang, Protectin DX restores Treg/T(h)17 cell balance in rheumatoid arthritis by inhibiting NLRP3 inflammasome via miR-20a. Cell Death Dis 12 (2021) 280.”
In the published article, the reference in the sentence “For example, taraxasterol and parthenolide suppress the activation of NLRP3 inflammasome by blocking the activation of NF-κB (127)” was incorrectly written as “(!!! INVALID CITATION!!! [103;104])”. It should be “J. Chen, W. Wu, M. Zhang, and C. Chen, Taraxasterol suppresses inflammation in IL-1β-induced rheumatoid arthritis fibroblast-like synoviocytes and rheumatoid arthritis progression in mice. Int Immunopharmacol 70 (2019) 274-283.” and “N. Li, Y. Wang, X. Wang, N. Sun, and Y.H. Gong, Pathway network of pyroptosis and its potential inhibitors in acute kidney injury. Pharmacol Res 175 (2022) 106033.”
In the published article, reference 52 (Z. Wang, Y. Kun, Z. Lei, W. Dawei, P. Lin, and W. Jibo, LncRNA MIAT downregulates IL-1β, TNF-ɑ to suppress macrophage inflammation but is suppressed by ATP-induced NLRP3 inflammasome activation. Cell Cycle 20 (2021) 194-203.) was incorrectly cited. It should be removed.
In the published article, reference 72 (X. Lu, L. Gilbert, X. He, J. Rubin, and M.S. Nanes, Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways. J Biol Chem 281 (2006) 6297-306.) was incorrectly cited. It should be removed.
In the published article, there was an error. “NLRP” was wrongly written in a section title instead of “NLRP3”.
A correction has been made to Section 3.2, NLRP inflammasome as a protective factor in RA. This sentence previously stated:
“NLRP inflammasome as a protective factor in RA”
The corrected sentence appears below:
“NLRP3 inflammasome as a protective factor in RA”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: inflammasome, NOD-like receptor protein 3 (NLRP3), rheumatoid arthritis, IL-1β, inflammation
Citation: Yin H, Liu N, Sigdel KR and Duan L (2023) Corrigendum: Role of NLRP3 inflammasome in rheumatoid arthritis. Front. Immunol. 14:1228176. doi: 10.3389/fimmu.2023.1228176
Received: 24 May 2023; Accepted: 30 June 2023;
Published: 18 July 2023.
Edited and Reviewed by:
Zhu Chen, University of Science and Technology of China, ChinaCopyright © 2023 Yin, Liu, Sigdel and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lihua Duan, lh-duan@163.com
†These authors have contributed equally to this work